HFZS
839725
Hangzhou SDIC Microelectronics Inc.
688130
Henan Liliang Diamond
301071
Sf Diamond Co., Ltd.
300179
Jiangsu Zhengdan Chemical Industry
300641
CN Stock MarketDetailed Quotes
600511 China National Medicines Corporation
- 34.69
- +0.04+0.12%
Not Open Dec 23 15:00 CST
26.17BMarket Cap12.09P/E (TTM)
35.14High34.32Low45.50KlotVolume34.60Open34.65Pre Close158.17MTurnover0.82%Turnover Ratio12.20P/E (Static)754.50MShares38.0052wk High1.58P/B19.20BFloat Cap26.3352wk Low38.12Limit Up553.35MShs Float60.06Historical High31.19Limit Down2.37%Amplitude-4.44Historical Low0.85Dividend TTM34.76Avg Price18.87KlotAsk2.46%Div YieldTTM100Lot Size24.69KlotBid
China National Medicines Corporation Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 4.10%38.03B | 2.55%24.76B | 7.98%12.12B | 9.23%49.7B | 5.75%36.53B | 9.70%24.14B | 1.50%11.23B | -2.09%45.5B | 0.73%34.54B | -0.31%22.01B |
| Operating revenue | 4.10%38.03B | 2.55%24.76B | 7.98%12.12B | 9.23%49.7B | 5.75%36.53B | 9.70%24.14B | 1.50%11.23B | -2.09%45.5B | 0.73%34.54B | -0.31%22.01B |
| Other operating revenue | ---- | 24.07%51.28M | ---- | 65.20%103.99M | ---- | 680.16%41.33M | ---- | 139.72%62.95M | ---- | -54.91%5.3M |
| Total operating cost | 4.33%36.31B | 2.68%23.63B | 8.04%11.58B | 9.20%47.19B | 6.10%34.8B | 9.79%23.01B | 1.26%10.72B | -2.55%43.22B | 0.36%32.8B | -0.73%20.96B |
| Operating cost | 4.92%35.36B | 3.27%23B | 8.77%11.27B | 9.67%45.7B | 6.20%33.7B | 9.79%22.27B | 0.93%10.36B | -2.71%41.68B | 0.32%31.74B | -0.70%20.29B |
| Operating tax surcharges | 9.79%88.94M | 24.61%57.35M | 17.52%26.82M | 2.51%114.74M | -2.53%81.01M | -12.11%46.02M | -31.11%22.82M | -6.74%111.93M | -4.32%83.12M | -0.19%52.36M |
| Operating expense | -14.58%582.15M | -18.09%388.69M | -15.37%201.45M | 0.61%962.38M | 0.67%681.55M | 13.17%474.51M | 21.42%238.03M | 1.70%956.5M | 1.58%677.03M | -3.15%419.28M |
| Administration expense | 0.57%309.74M | -0.57%200.45M | -4.45%100.53M | 7.23%467.13M | 7.03%307.98M | 8.10%201.61M | 8.86%105.22M | 4.75%435.62M | 6.80%287.75M | 9.76%186.5M |
| Financial expense | -218.13%-73.67M | -135.50%-52.69M | -25.98%-28.8M | -337.33%-126.13M | 12.90%-23.16M | -9.76%-22.37M | -28.57%-22.86M | -57.24%-28.84M | -100.79%-26.59M | -328.65%-20.38M |
| -Interest expense (Financial expense) | -30.98%24.27M | -39.64%15.57M | -45.09%7.32M | 17.46%31.57M | 86.91%35.16M | 89.92%25.79M | -4.82%13.33M | -38.51%26.88M | -53.57%18.81M | -48.78%13.58M |
| -Interest Income (Financial expense) | -45.21%-101.7M | -33.97%-73.51M | -4.91%-39.71M | -134.98%-166.37M | -24.26%-70.04M | -35.33%-54.87M | -10.56%-37.85M | -0.09%-70.8M | 5.30%-56.36M | -0.05%-40.55M |
| Research and development | -16.98%44.14M | -16.14%28.8M | -16.44%13.94M | 6.27%71.2M | 21.24%53.17M | 15.12%34.34M | 24.15%16.68M | 20.17%67M | 11.66%43.85M | 13.02%29.83M |
| Credit Impairment Loss | 4.08%-46.64M | -8.39%-43.37M | -224.09%-30.18M | 61.49%-9.17M | -17.04%-48.62M | -103.00%-40.01M | 42.23%-9.31M | 27.92%-23.8M | 11.74%-41.54M | 34.74%-19.71M |
| Asset Impairment Loss | 68.32%-6.83M | 57.07%-4.05M | 45.89%-2.79M | 107.56%388.87K | -107.58%-21.56M | 1.58%-9.44M | -76.58%-5.16M | 70.77%-5.14M | 53.98%-10.39M | -48.71%-9.59M |
| Other net revenue | 1.88%271.79M | 4.20%199.11M | 9.76%75.66M | 6.64%442.4M | 16.60%266.77M | 35.61%191.08M | 29.23%68.93M | 25.74%414.85M | 18.10%228.79M | 68.07%140.91M |
| Fair value change income | ---- | ---- | ---- | --10.82M | --34.73M | --34.73M | ---- | ---- | ---- | ---- |
| Invest income | 10.26%316.41M | 21.71%240.33M | 30.13%104.98M | 23.09%358.95M | 31.90%286.98M | 48.94%197.45M | 47.75%80.67M | 2.92%291.62M | 18.41%217.57M | 37.64%132.57M |
| -Including: Investment income associates | -2.73%320.21M | 10.05%243.25M | 18.19%102.19M | 19.89%456.54M | 24.01%329.19M | 34.29%221.04M | 22.10%86.46M | 0.15%380.8M | 4.07%265.44M | 12.63%164.59M |
| Asset deal income | -141.17%-136.75K | -111.75%-54.07K | 97.72%-2.37K | -95.04%83.44K | -78.22%332.13K | 5,435.12%460.36K | -3,795.40%-103.94K | 2,460.84%1.68M | 2,317.13%1.52M | 45.28%-8.63K |
| Other revenue | -39.79%8.98M | -20.79%6.25M | 28.87%3.65M | -45.96%81.32M | -75.80%14.92M | -79.03%7.9M | -84.05%2.84M | 54.72%150.49M | -22.67%61.63M | 55.64%37.65M |
| Operating profit | -0.23%1.99B | 0.50%1.33B | 7.02%613.8M | 9.26%2.94B | 1.20%1.99B | 11.05%1.32B | 9.21%573.52M | 10.12%2.69B | 9.28%1.97B | 13.44%1.19B |
| Add:Non operating Income | -54.22%1.34M | -46.98%990.47K | -28.26%629.91K | -73.18%3.01M | 61.87%2.93M | 236.52%1.87M | 84.17%878.08K | 173.35%11.21M | -38.21%1.81M | -62.13%555.09K |
| Less:Non operating expense | 132.04%24.77M | 3,391.89%12.77M | 189.27%892.27K | -9.71%16.47M | -24.06%10.67M | -94.28%365.57K | -61.76%308.45K | 177.78%18.24M | 375.54%14.06M | 3,136.25%6.39M |
| Total profit | -1.02%1.97B | -0.50%1.32B | 6.87%613.54M | 9.04%2.93B | 1.44%1.99B | 11.72%1.32B | 9.39%574.09M | 9.94%2.69B | 8.61%1.96B | 12.74%1.19B |
| Less:Income tax cost | -3.28%390.91M | -2.93%254.16M | -4.26%118.42M | 6.66%596.42M | -2.19%404.14M | 3.50%261.83M | 7.26%123.68M | 8.30%559.18M | 8.12%413.18M | 15.58%252.98M |
| Net profit | -0.44%1.57B | 0.09%1.06B | 9.93%495.12M | 9.67%2.33B | 2.41%1.58B | 13.95%1.06B | 9.98%450.41M | 10.38%2.13B | 8.74%1.54B | 12.00%932.6M |
| Net profit from continuing operation | -0.44%1.57B | 0.09%1.06B | 9.93%495.12M | 9.67%2.33B | 2.41%1.58B | 13.95%1.06B | 9.98%450.41M | 10.38%2.13B | 8.74%1.54B | 12.00%932.6M |
| Less:Minority Profit | -21.70%93.66M | -19.12%63.16M | -0.93%35.66M | 14.47%188.47M | 5.77%119.61M | 11.00%78.09M | 0.90%36M | -5.60%164.65M | -4.96%113.09M | 5.27%70.35M |
| Net profit of parent company owners | 1.30%1.48B | 1.62%1B | 10.87%459.45M | 9.26%2.15B | 2.14%1.46B | 14.19%984.58M | 10.85%414.41M | 11.97%1.96B | 9.99%1.43B | 12.59%862.25M |
| Earning per share | ||||||||||
| Basic earning per share | 1.30%1.9632 | 1.62%1.3261 | 10.85%0.6089 | 9.27%2.8443 | 2.15%1.9381 | 14.18%1.3049 | 10.86%0.5493 | 11.97%2.6031 | 9.99%1.8974 | 12.59%1.1428 |
| Diluted earning per share | 1.30%1.9632 | 1.62%1.3261 | 10.85%0.6089 | 9.27%2.8443 | 2.15%1.9381 | 14.18%1.3049 | 10.86%0.5493 | 11.97%2.6031 | 9.99%1.8974 | 12.59%1.1428 |
| Other composite income | -538.89%-4.45M | -1,222.22%-8.53M | -243.45%-5.85M | 577.86%5.1M | 140.00%1.01M | -72.16%759.79K | 2,171.43%4.08M | 61.53%-1.07M | 54.31%-2.53M | 178.86%2.73M |
| Other composite income of parent company owners | -538.89%-4.45M | -1,222.22%-8.53M | -243.45%-5.85M | 577.86%5.1M | 140.00%1.01M | -72.16%759.79K | 2,171.43%4.08M | 61.53%-1.07M | 54.31%-2.53M | 178.86%2.73M |
| Total composite income | -0.79%1.57B | -0.78%1.06B | 7.65%489.27M | 9.96%2.34B | 2.64%1.58B | 13.70%1.06B | 11.03%454.49M | 10.48%2.13B | 8.98%1.54B | 12.80%935.33M |
| Total composite income of parent company owners | 0.92%1.48B | 0.67%991.98M | 8.39%453.6M | 9.58%2.15B | 2.39%1.46B | 13.92%985.34M | 12.00%418.49M | 12.09%1.96B | 10.26%1.43B | 13.46%864.98M |
| Total composite income of minority owners | -21.70%93.66M | -19.12%63.16M | -0.93%35.66M | 14.47%188.47M | 5.77%119.61M | 11.00%78.09M | 0.90%36M | -5.60%164.65M | -4.96%113.09M | 5.27%70.35M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
